Advancing a class on top of statins
Investors & Media

Investor Overview

Webcast ImageGemphire Announces Top-Line Data from COBALT-1 Phase 2b Clinical Trial in HoFH Patients (Replay)06/28/17 at 4:30 p.m. ET

Gemphire Announces Top-Line Data from COBALT-1 Phase 2b Clinical Trial in HoFH Patients
Wednesday, June 28, 2017 4:30 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Gemphire is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease. Dyslipidemia is generally characterized by an elevation of low-density lipoprotein cholesterol (LDL-C), or bad cholesterol, triglycerides, or fat in the blood, or both... More >>

NASDAQ | GEMP (Common Stock)

$12.27

 0.43 (3.63%)

High$12.59
Low$11.99
Volume116,052
Market Cap$130,062,552

06/28/17  4:00 p.m. ET

Data provided by Nasdaq. Minimum 15 minutes delayed.
Stock chart for: GEMP.O.  Currently trading at $12.27 with a 52 week high of $13.98 and a 52 week low of $7.25.

Gemphire Announces Top-Line Data from COBALT-1 Phase 2b Clinical Trial in HoFH Patients

06/28/17

Read More

Gemphire to Present at the LD Micro Invitational and the Jefferies 2017 Global Healthcare Conference

06/01/17

Read More

Gemphire Therapeutics Announces Departure of Its Chief Executive Officer Mina Sooch

05/30/17

Read More


There are currently no events scheduled.